Association between the CYP1A2 rs762551 Polymorphism and Bladder Cancer Susceptibility: a Meta-Analysis Based on Case-Control Studies |
Zeng, Yong
(Department of Cardiothoracic Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University)
Jiang, Hua-Yong (Department of Radiation Oncology, Beijing Military General Hospital) Wei, Li (Department of Oncology, the 401 hospital of PLA) Xu, Wei-Dong (Department of Radiation Oncology, Beijing Military General Hospital) Wang, Ya-Jie (Department of Oncology, Changhai Hospital, Second Military Medical University) Wang, Ya-Di (Department of Radiation Oncology, Beijing Military General Hospital) Liu, Chuan (Department of Oncology, Changhai Hospital, Second Military Medical University) |
1 | Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48 |
2 | Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2008). How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol, 37, 136-46. DOI |
3 | Miranda CL, Yang YH, Henderson MC, et al (2000). Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4, 5-f]quinoline, mediated by cDNAexpressed human CYP1A2. Drug Metab Dispos, 28, 1297-302. |
4 | Nordmark A, Lundgren S, Cnattingius S, Rane A (1999). Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br J Clin Pharmacol, 47, 397-402. |
5 | Pavanello S, Simioli P, Lupi S, Gregorio P, Clonfero E (2002). Exposure levels and cytochrome P450 1A2 activity, but not N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers. Cancer Epidemiol Biomarkers Prev, 11, 998-1003. |
6 | Pavanello S, Mastrangelo G, Placidi D, et al (2010). CYP1A2 polymorphisms, occupational and environmental exposures and risk of bladder cancer. Eur J Epidemiol, 25, 491-500. DOI |
7 | Qiu LX, Yao L, Mao C, Yu KD, Zhan P, et al (2010). Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: A meta-analysis involving 17,600 subjects. Breast Cancer Res Treat, 122, 521-5. DOI |
8 | Rodriguez-Antona C, Ingelman-Sundberg M (2006). Cytochrome P450 pharmacogenetics and cancer. Oncogene, 25, 1679-91. DOI |
9 | Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y (2009). CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol, 41, 259-66. DOI |
10 | Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. DOI |
11 | Bozina N, Bradamante V, Lovric M (2009). Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol, 60, 217-42 |
12 | Butler MA, Lang NP, Young JF, et al (1992). Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 2, 116-27. DOI |
13 | Chung WG, Kang JH, Park CS, Cho MH, Cha YN (2000). Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. Clin Pharmacol Ther, 67, 258-66. DOI |
14 | Caporaso N, Landi MT, Vineis P (1991). Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics, 1, 4-19 DOI |
15 | Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. DOI |
16 | Sesardic D, Boobis AR, Edwards RJ, Davies DS (1988). A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the odeethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol, 26, 363-72. DOI |
17 | Sachse C, Bhambra U, Smith G, et al (2003). Colorectal Cancer Study Group. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol, 55, 68-76. DOI |
18 | Sachse C, Brockmoller J, Bauer S, Roots I (1999). Functional significance of a C>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol, 47, 445-9. |
19 | Sangrajrang S, Sato Y, Sakamoto H, et al (2009). Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer, 125, 837-43. DOI |
20 | Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. DOI |
21 | Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies inmeta-analyses. Eur J Epidemiol, 25, 603-5. DOI |
22 | Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR (2000). Empirical assessment of effect of publication bias on metaanalysis. BMJ, 320, 1574-7. DOI |
23 | Tsukino H, Kuroda Y, Nakao H, et al (2004). Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol, 130, 99-106. DOI |
24 | Villanueva CM, Silverman DT, Murta-Nascimento C, et al (2009). Coffee consumption, genetic susceptibility and bladder cancer risk. Cancer Causes Control, 20, 121-7. DOI |
25 | Figueroa JD, Malats N, Garcia-Closas M, et al (2008). Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis, 29, 1955-62. DOI |
26 | Cui X, Lu X, Hiura M, et al (2013). Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population. Environ Health Prev Med, 18, 136-42. DOI |
27 | DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88 DOI |
28 | Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in metaanalysis detected by a simple graphical test. BMJ, 315, 629-34. DOI |
29 | Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. DOI |
30 | Ioannidis JP, Boffetta P, Little J, et al (2008). Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol, 37, 120-32. DOI |
31 | Kiemeney LA, Grotenhuis AJ, Vermeulen SH, Wu X (2009). Genome-wide association studies in bladder cancer: first results and potential relevance. Curr Opin Urol, 19, 540-6. DOI |
32 | Kiltie AE (2010). Common predisposition alleles for moderately common cancers: bladder cancer. Curr Opin Genet Dev, 20, 218-24. DOI |
33 | Li D, Jiao L, Li Y, et al (2006). Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis, 27, 103-11. |
34 | Mandal RK, Dubey S, Panda AK, Mittal RD (2014). Genetic variants of NQO1 gene increase bladder cancer risk in Indian population and meta-analysis. Tumour Biol, 35, 6415-23 DOI |
35 | Xiong T, Yang J, Wang H, et al (2014). The association between the Lys751Gln polymorphism in the XPD gene and the risk of bladder cancer. Mol Biol Rep, 41, 2629-34. DOI |
36 | Volanis D, Kadiyska T, Galanis A, et al (2010). Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett, 193, 131-7. DOI |
37 | Wang Y, Kong CZ, Zhang Z, Yang CM, Li J (2014). Relationships between CYP1A1 genetic polymorphisms and bladder cancer risk: a meta-analysis. DNA Cell Biol, 33, 171-81. DOI |
![]() |